Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference
Akero Therapeutics (Nasdaq: AKRO) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 15, 2021, at 11:45 a.m. (ET).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Akero Therapeutics (Nasdaq: AKRO) will present at the Morgan Stanley Virtual Global Healthcare Conference on September 15, 2021, at 11:45 a.m. (ET). The presentation will highlight the company's innovative approach to treating non-alcoholic steatohepatitis (NASH) with its investigational drug, efruxifermin (EFX). EFX aims to offer potential benefits as a best-in-class medicine, with ongoing Phase 2b trials evaluating its effectiveness in patients with varying fibrosis stages. A live webcast of the presentation will be available on Akero's investor relations website.
Details
News Market Reaction – AKRO
The recorded move for AKRO in the trading session of this news was +1.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that members of the management team will present at the Morgan Stanley Virtual Global Healthcare Conference on Wednesday, September 15, 2021 at 11:45 a.m. (ET).
A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.
About Akero Therapeutics
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero’s investigational drug product candidate, efruxifermin (EFX) is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body. EFX is designed to offer convenient once-weekly subcutaneous dosing. The consistency and magnitude of effects observed in clinical studies position EFX to be a potentially best-in-class medicine, if approved, for treatment of NASH. EFX is currently being evaluated in two Phase 2b clinical trials: the HARMONY study in pre-cirrhotic patients with F2/F3 fibrosis and the SYMMETRY study in cirrhotic (F4) patients. Akero is headquartered in South San Francisco. Visit www.akerotx.com for more information.
Investor Contact:
Christina Tartaglia
Stern Investor Relations, Inc.
212.362.1200
christina.tartaglia@sternir.com
Media Contact:
650.487.6488
media@akerotx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.